Literature DB >> 24166531

Methodologic diligence is needed to define and validate tumor-size response metrics to predict overall survival in first-line metastatic colorectal cancer.

Ulrich R Mansmann1, Rüdiger P Laubender.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24166531     DOI： 10.1200/JCO.2013.51.2954

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Authors:  Yu Sunakawa; Akihito Tsuji; Tadamichi Denda; Yoshihiko Segawa; Yuji Negoro; Ken Shimada; Mitsugu Kochi; Masato Nakamura; Masahito Kotaka; Hiroaki Tanioka; Akinori Takagane; Satoshi Tani; Tatsuro Yamaguchi; Takanori Watanabe; Masahiro Takeuchi; Masashi Fujii; Wataru Ichikawa
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

2.  On the relationship between tumour growth rate and survival in non-small cell lung cancer.

Authors:  Hitesh B Mistry
Journal:  PeerJ       Date:  2017-11-29       Impact factor: 2.984

3.  Complex chest wall surgery to prevent vascular complications after immunotherapy and radiation treatment.

Authors:  James J Choi; Robert J Allen; Manjit S Bains; Marc A Cohen; Yao Yu; Nassrene Elmadhun; David R Jones; Gaetano Rocco
Journal:  JTCVS Tech       Date:  2020-08-15

4.  Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Authors:  E Chigutsa; A J Long; J E Wallin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-13

5.  Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus de novo stage pI cohort: A propensity score-matched analysis.

Authors:  Ning Li; Jing Jin; Jing Yu; Shuai Li; Yuan Tang; Hua Ren; Wenyang Liu; Shulian Wang; Yueping Liu; Yongwen Song; Hui Fang; Zihao Yu; Yexiong Li
Journal:  Chin J Cancer Res       Date:  2018-06       Impact factor: 5.087
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.